Toxicological considerations for intravitreal drugs

Bibliography

• Brechner RJ, Rosenfeld PJ, Babish JD, Caplan S, Pharmacotherapy for neovascular age-related macular degeneration: an analysis of the 100% 2008 medicare fee-for-service part B claims file. Am J Ophthalmol 2011;151(5):887-95
   PubMed Web of Science ®Google Scholar
• Ohm J. Uber die behandlung der netzhautablosung durch operative entleerung der subretinalen flussigkeit und einspritzung von luft in den glaskoper. Graefes Arch Clin Exp Ophthalmol 1911;79:442-50
   Google Scholar
• Friedman AH, Orellana J, Freeman WR, Cytomegalovirus retinitis: a manifestation of the acquired immune deficiency syndrome (AIDS). Br J Ophthalmol 1983;67:372-80
   PubMed Web of Science ®Google Scholar
• Bhatnagar P, Spaide RF, Takahashi BS, Ranibizumab for treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina 2007;7:846-50
   Google Scholar
• Blick SK, Keating GM, Wagstaff AJ. Ranibizumab. Drugs 2007;67:1199-206; discussion 1207–1209
   PubMed Web of Science ®Google Scholar
• Novack GD. Pharmacotherapy for the treatment of choroidal neovascularization due to age-related macular degeneration. Annu Rev Pharmacol Toxicol 2008;48:61-78
   PubMed Web of Science ®Google Scholar
• Vavvas D, D'Amico DJ. Pegaptanib (Macugen): treating neovascular age-related macular degeneration and current role in clinical practice. Ophthalmol Clin North Am 2006;19:353-60
   PubMedGoogle Scholar
• Maia M, Farah ME, Belfort RN, Effects of intravitreal triamcinolone acetonide injection with and without preservative. Br J Ophthalmol 2007;91:1122-4
   PubMed Web of Science ®Google Scholar
• Maia M, Penha FM, Farah ME, Subretinal injection of preservative-free triamcinolone acetonide and supernatant vehicle in rabbits: an electron microscopy study. Graefes Arch Clin Exp Ophthalmol 2008;246:379-88
   PubMed Web of Science ®Google Scholar
• Azab M, Boyer DS, Bressler NM, Verteporfin therapy of subfoveal minimally classic choroidal neovascularization in age-related macular degeneration: 2-year results of a randomized clinical trial. Arch Ophthalmol 2005;123:448-57
   PubMed Web of Science ®Google Scholar
• Aggio FB, Farah ME, Silva WC, Melo GB. Intravitreal bevacizumab for exudative age-related macular degeneration after multiple treatments. Graefes Arch Clin Exp Ophthalmol 2007;245:215-20
   PubMed Web of Science ®Google Scholar
• Jonas JB, Libondi T, Ihloff AK, Visual acuity change after intravitreal bevacizumab for exudative age-related macular degeneration in relation to subfoveal membrane type. Acta Ophthalmol Scand 2007;85:563-5
   PubMedGoogle Scholar
• Arevalo JF, Fromow-Guerra J, Sanchez JG, Primary intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration: results of the Pan-American Collaborative Retina Study Group at 12 months follow-up. Retina 2008;28:1387-94
   PubMed Web of Science ®Google Scholar
• Avery RL. Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment. Retina 2006;26:352-4
   PubMed Web of Science ®Google Scholar
• Bashshur ZF, Haddad ZA, Schakal AR, Intravitreal bevacizumab for treatment of neovascular age-related macular degeneration: the second year of a prospective study. Am J Ophthalmol 2009;148:59-65 e1
   PubMed Web of Science ®Google Scholar
• Bonini-Filho M, Costa RA, Calucci D, Intravitreal bevacizumab for diabetic macular edema associated with severe capillary loss: one-year results of a pilot study. Am J Ophthalmol 2009;147:1022-30, 30 e1–5
   PubMed Web of Science ®Google Scholar
• Arevalo JF, Garcia-Amaris RA, Roca JA, Primary intravitreal bevacizumab for the management of pseudophakic cystoid macular edema: pilot study of the Pan-American Collaborative Retina Study Group. J Cataract Refract Surg 2007;33:2098-105
   PubMed Web of Science ®Google Scholar
• Donati MC, Virgili G, Bini A, Intravitreal bevacizumab (Avastin) for choroidal neovascularization in angioid streaks: a case series. Ophthalmologica 2009;223:24-7
   PubMed Web of Science ®Google Scholar
• Iriyama A, Chen YN, Tamaki Y, Yanagi Y. Effect of anti-VEGF antibody on retinal ganglion cells in rats. Br J Ophthalmol 2007;91:1230-3
   PubMed Web of Science ®Google Scholar
• Luke M, Warga M, Ziemssen F, Effects of bevacizumab on retinal function in isolated vertebrate retina. Br J Ophthalmol 2006;90:1178-82
   PubMed Web of Science ®Google Scholar
• Luthra S, Narayanan R, Marques LE, Evaluation of in vitro effects of bevacizumab (Avastin) on retinal pigment epithelial, neurosensory retinal, and microvascular endothelial cells. Retina 2006;26:512-18
   PubMed Web of Science ®Google Scholar
• Bakri SJ, Cameron JD, McCannel CA, Absence of histologic retinal toxicity of intravitreal bevacizumab in a rabbit model. Am J Ophthalmol 2006;142:162-4
   PubMed Web of Science ®Google Scholar
• Heiduschka P, Fietz H, Hofmeister S, Penetration of bevacizumab through the retina after intravitreal injection in the monkey. Invest Ophthalmol Vis Sci 2007;48:2814-23
   PubMed Web of Science ®Google Scholar
• Inan UU, Avci B, Kusbeci T, Preclinical safety evaluation of intravitreal injection of full-length humanized vascular endothelial growth factor antibody in rabbit eyes. Invest Ophthalmol Vis Sci 2007;48:1773-81
   PubMed Web of Science ®Google Scholar
• Manzano RP, Peyman GA, Khan P, Kivilcim M. Testing intravitreal toxicity of bevacizumab (Avastin). Retina 2006;26:257-61
   PubMed Web of Science ®Google Scholar
• Peters S, Heiduschka P, Julien S, Ultrastructural findings in the primate eye after intravitreal injection of bevacizumab. Am J Ophthalmol 2007;143:995-1002
   PubMed Web of Science ®Google Scholar
• Chan CK, Lin SG. Retinal pigment epithelial tear after ranibizumab therapy for subfoveal fibrovascular pigment epithelial detachment. Eur J Ophthalmol 2007;17:674-6
   PubMed Web of Science ®Google Scholar
• Rodrigues EB, Shiroma H, Meyer CH, Metrorrhagia after intravitreal injection of bevacizumab. Acta Ophthalmol Scand 2007;85:915-16
   PubMedGoogle Scholar
• Adelman RA, Zheng Q, Mayer HR. Persistent ocular hypertension following intravitreal bevacizumab and ranibizumab injections. J Ocul Pharmacol Ther 2010;26:105-10
   PubMed Web of Science ®Google Scholar
• Kahook MY, Kimura AE, Wong LJ, Sustained elevation in intraocular pressure associated with intravitreal bevacizumab injections. Ophthalmic Surg Lasers Imaging 2009;40:293-5
   PubMed Web of Science ®Google Scholar
• Semoun O, Blumen-Ohana E, de Preobrajensky N, Nordmann JP. Acute angle-closure glaucoma complicating an intravitreal injection of bevacizumab. J Fr Ophtalmol 2009;32:58 e1-4
   PubMed Web of Science ®Google Scholar
• Shima C, Sakaguchi H, Gomi F, Complications in patients after intravitreal injection of bevacizumab. Acta Ophthalmol 2008;86:372-6
   PubMed Web of Science ®Google Scholar
• Shouten JS, La Heij EC, Webers CA, A systematic review on the effect of bevacizumab in exudative age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 2009;247:1-11
   PubMed Web of Science ®Google Scholar
• Martin DF, Maguire MG, Ying GS, CATT Rsearch group. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011;364(20):1897-908
   PubMed Web of Science ®Google Scholar
• Fung AE, Rosenfeld PJ, Reichel E. The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide. Br J Ophthalmol 2006;90:1344-9
   PubMed Web of Science ®Google Scholar
• Brown DM, Kaiser PK, Michels M, Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355:1432-44
   PubMed Web of Science ®Google Scholar
• Brown DM, Michels M, Kaiser PK, Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study. Ophthalmology 2009;116:57-65 e5
   PubMed Web of Science ®Google Scholar
• Mitchell P, Korobelnik JF, Lanzetta P, Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials. Br J Ophthalmol 2010;94:2-13
   PubMed Web of Science ®Google Scholar
• Rosenfeld PJ. Intravitreal avastin: the low cost alternative to lucentis? Am J Ophthalmol 2006;142:141-3
   PubMed Web of Science ®Google Scholar
• Rosenfeld PJ. New treatments for age-related macular degeneration. Lancet 2007;370:1479; author reply 1480
   PubMedGoogle Scholar
• Holash J, Davis S, Papadopoulos N, VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci USA 2002;99:11393-8
   PubMed Web of Science ®Google Scholar
• Chappelow AV, Kaiser PK. Neovascular age-related macular degeneration: potential therapies. Drugs 2008;68:1029-36
   PubMed Web of Science ®Google Scholar
• Rudge JS, Thurston G, Davis S, VEGF trap as a novel antiangiogenic treatment currently in clinical trials for cancer and eye diseases, and VelociGene- based discovery of the next generation of angiogenesis targets. Cold Spring Harb Symp Quant Biol 2005;70:411-18
   PubMedGoogle Scholar
• Nguyen QD, Shah SM, Browning DJ, A Phase I study of intravitreal vascular endothelial growth factor trap-eye in patients with neovascular age-related macular degeneration. Ophthalmology 2009;116:2141-8 e1
   PubMed Web of Science ®Google Scholar
• Regeneron Pharmaceuticals. Vascular Endothelial Growth Factor(VEGF)Trap-Eye:Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration(AMD). ClinicalTrials.gov NCT00509795. Available from: http://clinicaltrials.gov/ct2/show/NCT00509795?term=NCT00509795&rank=1
   Google Scholar
• Zhang M, Yu D, Yang C, The pharmacology study of a new recombinant human VEGF receptor-fc fusion protein on experimental choroidal neovascularization. Pharm Res 2009;26:204-10
   PubMed Web of Science ®Google Scholar
• Suto K, Yamazaki Y, Morita T, Mizuno H. Crystal structures of novel vascular endothelial growth factors (VEGF) from snake venoms: insight into selective VEGF binding to kinase insert domain-containing receptor but not to fms-like tyrosine kinase-1. J Biol Chem 2005;280:2126-31
   PubMed Web of Science ®Google Scholar
• Dick AD, Forrester JV, Liversidge J, Cope AP. The role of tumour necrosis factor (TNF-alpha) in experimental autoimmune uveoretinitis (EAU). Prog Retin Eye Res 2004;23:617-37
   PubMed Web of Science ®Google Scholar
• Imrie FR, Dick AD. Biologics in the treatment of uveitis. Curr Opin Ophthalmol 2007;18:481-6
   PubMed Web of Science ®Google Scholar
• Giansanti F, Ramazzotti M, Vannozzi L, A pilot study on ocular safety of intravitreal infliximab in a rabbit model. Invest Ophthalmol Vis Sci 2008;49:1151-6
   PubMed Web of Science ®Google Scholar
• Fauser S, Kalbacher H, Alteheld N, Pharmacokinetics and safety of intravitreally delivered etanercept. Graefes Arch Clin Exp Ophthalmol 2004;242:582-6
   PubMed Web of Science ®Google Scholar
• Kivilcim M, Peyman GA, Kazi AA, Intravitreal toxicity of high-dose etanercept. J Ocul Pharmacol Ther 2007;23:57-62
   PubMed Web of Science ®Google Scholar
• Manzano RP, Peyman GA, Carvounis PE, Ocular toxicity of intravitreous adalimumab (Humira) in the rabbit. Graefes Arch Clin Exp Ophthalmol 2008;246:907-11
   PubMed Web of Science ®Google Scholar
• Galor A, Perez VL, Hammel JP, Lowder CY. Differential effectiveness of etanercept and infliximab in the treatment of ocular inflammation. Ophthalmology 2006;113:2317-23
   PubMed Web of Science ®Google Scholar
• Tynjala P, Lindahl P, Honkanen V, Infliximab and etanercept in the treatment of chronic uveitis associated with refractory juvenile idiopathic arthritis. Ann Rheum Dis 2007;66:548-50
   PubMed Web of Science ®Google Scholar
• Wu L, Hernandez-Bogantes E, Roca JA, Intravitreal tumor necrosis factor inhibitors in the treatment of refractory diabetic macular edema: a pilot study from the Pan-American Collaborative Retina Study Group. Retina 2011;31:298-303
   PubMed Web of Science ®Google Scholar
• Giganti M, Beer PM, Lemanski N, Adverse events after intravitreal infliximab (Remicade). Retina 2010;30:71-80
   PubMed Web of Science ®Google Scholar
• Kumar R, Knick VB, Rudolph SK, Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity. Mol Cancer Ther 2007;6:2012-21
   PubMed Web of Science ®Google Scholar
• Takahashi K, Saishin Y, King AG, Suppression and regression of choroidal neovascularization by the multitargeted kinase inhibitor pazopanib. Arch Ophthalmol 2009;127:494-9
   PubMed Web of Science ®Google Scholar
• Yafai Y, Niemeyer M, Yasukawa T, Inhibition of experimental choroidal neovascularization by the VEGF receptor inhibitor pazopanib (GW786034B). Invest Ophthalmol Vis Sci 2008;49:E-abstract 534
   Google Scholar
• McLaughlin MM, Bayliffe A, Hunt T, A multi-targeted receptor tyrosine kinase inhibitor for the treatment of neovascular AMD: results of a healthy volunteer safety and tolerability study of pazopanib eye drops. Invest Ophthalmol Vis Sci 2009;50:E-abstract 5008
   Google Scholar
• GlaxoSmithKline. An Extension to Study MD7108240. ClinicalTrials.gov NCT00733304. Available from: http://clinicaltrials.gov/ct2/show/NCT00733304?term=NCT00733304&rank=1
   Google Scholar
• Dib E, Maia M, Costa EPF, In vitro and in vivo toxicity of sutinib maleate. Invest Ophthalmol Vis Sci 2010;51:E-abstract 2817
   Google Scholar
• Hancock HA, Guidry C, Read RW, Acute aminoglycoside retinal toxicity in vivo and in vitro. Invest Ophthalmol Vis Sci 2005;46:4804-8
   PubMed Web of Science ®Google Scholar
• D'Amico DJ, Caspers-Velu L, Libert J, Comparative toxicity of intravitreal aminoglycoside antibiotics. Am J Ophthalmol 1985;100:264-75
   PubMed Web of Science ®Google Scholar
• Mochizuki K, Torisaki M, Yamashita Y, Effects of aminoglycosides on the rabbit in-vivo ERG. Nippon Ganka Gakkai Zasshi 1989;93:80-5
   PubMedGoogle Scholar
• Oum BS, D'Amico DJ, Kwak HW, Wong KW. Intravitreal antibiotic therapy with vancomycin and aminoglycoside: examination of the retinal toxicity of repetitive injections after vitreous and lens surgery. Graefes Arch Clin Exp Ophthalmol 1992;230:56-61
   PubMed Web of Science ®Google Scholar
• Almeida LN, Canedo MG, Almeida RN, Macular infarction after intravitreal injection of amikacin: case report. Arq Bras Oftalmol 2005;68:837-40
   PubMedGoogle Scholar
• Campochiaro PA, Green WR. Toxicity of intravitreous ceftazidime in primate retina. Arch Ophthalmol 1992;110:1625-9
   PubMed Web of Science ®Google Scholar
• Sonmez M, Unal MH, Yildiz TF, Gulecek O. Retinal toxicity of intraocular vancomycin and ceftazidime in vitrectomized rabbit eyes. Drug Chem Toxicol 2006;29:125-34
   PubMed Web of Science ®Google Scholar
• Hegazy HM, Kivilcim M, Peyman GA, Evaluation of toxicity of intravitreal ceftazidime, vancomycin, and ganciclovir in a silicone oil-filled eye. Retina 1999;19:553-7
   PubMed Web of Science ®Google Scholar
• Borhani H, Peyman GA, Wafapoor H. Use of vancomycin in vitrectomy infusion solution and evaluation of retinal toxicity. Int Ophthalmol 1993;17:85-8
   PubMed Web of Science ®Google Scholar
• Zimmer-Galler IE, Santos A, Haller JA, Campochiaro PA. Management of endophthalmitis in a silicone oil-filled eye. Retina 1997;17:507-9
   PubMed Web of Science ®Google Scholar
• Fiscella RG. Physical incompatibility of vancomycin and ceftazidime for intravitreal injection. Arch Ophthalmol 1993;111:730
   PubMed Web of Science ®Google Scholar
• Wiechens B, Grammer JB, Johannsen U, Experimental intravitreal application of ciprofloxacin in rabbits. Ophthalmologica 1999;213:120-8
   PubMed Web of Science ®Google Scholar
• Kernt M, Neubauer AS, De Kaspar HM, Kampik A. Intravitreal voriconazole: in vitro safety-profile for fungal endophthalmitis. Retina 2009;29:362-70
   PubMed Web of Science ®Google Scholar
• Aydin E, Kazi AA, Peyman GA, Esfahani MR. Intravitreal toxicity of moxifloxacin. Retina 2006;26:187-90
   PubMed Web of Science ®Google Scholar
• Thompson AM. Ocular toxicity of fluoroquinolones. Clin Experiment Ophthalmol 2007;35:566-77
   PubMed Web of Science ®Google Scholar
• Khan FA, Slain D, Khakoo RA. Candida endophthalmitis: focus on current and future antifungal treatment options. Pharmacotherapy 2007;27:1711-21
   PubMed Web of Science ®Google Scholar
• Mochizuki K, Yamashita Y, Torisaki T, Intraocular penetration and effect on the retina of fluconazole. Lens Eye Toxic Res 1992;9:537-46
   PubMedGoogle Scholar
• Cheng CK, Yang CH, Hsueh PR, Vitrectomy with fluconazole infusion: retinal toxicity, pharmacokinetics, and efficacy in the treatment of experimental candidal endophthalmitis. J Ocul Pharmacol Ther 2004;20:430-8
   PubMed Web of Science ®Google Scholar
• Hariprasad SM, Mieler WF, Lin TK, Voriconazole in the treatment of fungal eye infections: a review of current literature. Br J Ophthalmol 2008;92:871-8
   PubMed Web of Science ®Google Scholar
• Gao H, Pennesi M, Shah K, Safety of intravitreal voriconazole: electroretinographic and histopathologic studies. Trans Am Ophthalmol Soc 2003;101:183-9; discussion 189
   PubMedGoogle Scholar
• Sen P, Gopal L, Sen PR. Intravitreal voriconazole for drug-resistant fungal endophthalmitis: case series. Retina 2006;26:935-9
   PubMed Web of Science ®Google Scholar
• Jaffe GJ, Yang CH, Guo H, Safety and pharmacokinetics of an intraocular fluocinolone acetonide sustained delivery device. Invest Ophthalmol Vis Sci 2000;41:3569-75
   PubMed Web of Science ®Google Scholar
• Holekamp NM, Thomas MA, Pearson A. The safety profile of long-term, high-dose intraocular corticosteroid delivery. Am J Ophthalmol 2005;139:421-8
   PubMed Web of Science ®Google Scholar
• Kwak HW, D'Amico DJ. Evaluation of the retinal toxicity and pharmacokinetics of dexamethasone after intravitreal injection. Arch Ophthalmol 1992;110:259-66
   PubMed Web of Science ®Google Scholar
• Yu SY, Damico FM, Viola F, Retinal toxicity of intravitreal triamcinolone acetonide: a morphological study. Retina 2006;26:531-6
   PubMed Web of Science ®Google Scholar
• Ishibashi T, Miki K, Sorgente N, Effects of intravitreal administration of steroids on experimental subretinal neovascularization in the subhuman primate. Arch Ophthalmol 1985;103:708-11
   PubMed Web of Science ®Google Scholar
• Arevalo JF, Fromow-Guerra J, Quiroz-Mercado H, Primary intravitreal bevacizumab (Avastin) for diabetic macular edema: results from the Pan-American Collaborative Retina Study Group at 6-month follow-up. Ophthalmology 2007;114:743-50
   PubMed Web of Science ®Google Scholar
• Dyer D, Callanan D, Bochow T, Clinical evaluation of the safety and efficacy of preservative-free triamcinolone (triesence [triamcinolone acetonide injectable suspension] 40 mg/ml) for visualization during pars plana vitrectomy. Retina 2009;29:38-45
   PubMed Web of Science ®Google Scholar
• Moshfeghi AA, Nugent AK, Nomoto H, Triamcinolone acetonide preparations: impact of crystal size on in vitro behavior. Retina 2009;29:689-98
   PubMed Web of Science ®Google Scholar
• Kai W, Yanrong J, Xiaoxin L. Vehicle of triamcinolone acetonide is associated with retinal toxicity and transient increase of lens density. Graefes Arch Clin Exp Ophthalmol 2006;244:1152-9
   PubMed Web of Science ®Google Scholar
• Lang Y, Leibu R, Shoham N, Evaluation of intravitreal kenalog toxicity in humans. Ophthalmology 2007;114:724-31
   PubMed Web of Science ®Google Scholar
• Abramson DH, Dunkel IJ, Brodie SE, A Phase I/II study of direct intraarterial (ophthalmic artery) chemotherapy with melphalan for intraocular retinoblastoma initial results. Ophthalmology 2008;115(8):1398-404, 1404 e1
   PubMed Web of Science ®Google Scholar
• Macky TA, Helmy D, El Shazly N. Retinal toxicity of triamcinolone's vehicle (benzyl alcohol): an electrophysiologic and electron microscopic study. Graefes Arch Clin Exp Ophthalmol 2007;245:817-24
   PubMed Web of Science ®Google Scholar
• Rodriguez-Coleman H, Yuan P, Kim H, Intravitreal injection of triamcinolone for diffuse macular edema. Arch Ophthalmol 2004;122:1085-6; author reply 1086–1088
   PubMed Web of Science ®Google Scholar
• Macky TA, Oelkers C, Rix U, Synthesis, pharmacokinetics, efficacy, and rat retinal toxicity of a novel mitomycin C-triamcinolone acetonide conjugate. J Med Chem 2002;45:1122-7
   PubMed Web of Science ®Google Scholar
• Lang Y, Zemel E, Miller B, Perlman I. Retinal toxicity of intravitreal kenalog in albino rabbits. Retina 2007;27:778-88
   PubMed Web of Science ®Google Scholar
• Li Q, Wang J, Yang L, A moephologic study of retinal toxicity induced by triamcinolone acetonide vehicles in rabbit eyes. Retina 2008;28:504-10
   PubMed Web of Science ®Google Scholar
• Loewenstein A, Zemel E, Lazar M, Perlman I. The effects of Depo-Medrol preservative on the rabbit visual system. Invest Ophthalmol Vis Sci 1991;32:3053-60
   PubMed Web of Science ®Google Scholar